Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma

Chinese Medical Journal

Volumn 125, Issue 8, 2012, Pages 1410-1415

  Yan, Hong Jiang ^a   Wang, Ren Ben ^a   Zhu, Kun li ^a   Jiang, Shu Mei ^a   Zhao, Wei ^a   Xu, Xiao Qing ^a   Feng, Rui ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Carcinoembryonic antigen; Chemoradiotherapy; Cytokeratin 19 fragment antigen 21 1; Esophageal squamous cell carcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 19 FRAGMENT ANTIGEN 21-1; FLUOROURACIL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KERATIN-19; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84860481185     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.08.009     Document Type: Article

References (29)

1. Coia LR. Chemoradiation as primary management of esophageal cancer. Semin Oncol 1994; 21: 483-492.
2. Forastier AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993; 11: 1118-1123.
3. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
4. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-284.
5. Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 1995; 25: 261-266.
6. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-2921.
7. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any)M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003; 57: 425-433.
8. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
9. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
10. Mao YS, Zhang DC, Zhao XH, Wang LJ, Qi J, Li XX. Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer. Chin J Oncol (Chin) 2003; 25: 457-460.
11. Mroczko B, Kozłowski M, Groblewska M, Łukaszewicz M, Nikliński J, Jelski W, et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta 2008; 389: 61-66.
12. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004; 28: 680-685.
13. Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 2009; 14: 480-485.
14. Stieber P, Dienemann H, Hasholzner U, Muller C, Poley S, Hofmann K, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 1993; 31: 689-694.
15. Bodenmuller H, Donie F, Kaufmann M, Banauch D. The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994; 9: 70-74.
16. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61-66.
17. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. CYFRA 21-1: a new marker in lung cancer. Cancer 1993; 72: 707-713.
18. Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 1995; 71: 160-165.
19. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107: 2842-2849.
20. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997; 79: 1647-1655.
21. Brockmann JG, Nottberg H, Glodny B, Sprakel B, Senninger N. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Anticancer Res 2000; 20: 4899-4904.
22. Quillien V, Raoul JL, Laurent JF, Meunier B, Le Prise E. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 1998; 5: 1561-1565.
23. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 2000; 89: 1413-1417.
24. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esoph 1998; 11: 35-39.
25. Wakatsuki M, Suzuki Y, Nakamoto S, Ohno T, Ishikawa H, Kiyohara H, et al. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy. J Gastroenterol Hepatol 2007; 22: 715-719.
26. Kunisaki C, Imada T, Yamada R, Hatori S, Kinbara K, Watai K, et al. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma. Hepatogastroenterology 2006; 53: 366-371.
27. Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol 2007; 37: 652-657.
28. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009; 27: 857-871.
29. Sarbia M, Ott N, Pühringer-Oppermann F, Brücher BL. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Brit J Cancer 2007; 97: 1404-1408.